Conclusion and Perspectives
While our understanding of Ras signaling is significant and many of the signaling components and pathways activated by Ras have been delineated, it is also likely that much remains to be determined. The discovery of additional downstream effectors of Ras continues and reveals further diversity and complexity in the cytoplasmic signaling activities of Ras. The recent identification of PLC3 as a Ras effector links Ras activity directly to the actions of second messengers, calcium and diacylglycerol, that in turn cause pleotropic cellular responses. Conversely, some effectors of Ras (Nore1 and RASSF1) may promote apoptosis rather than oncogenesis. How these effectors may contribute to the mechanism of Ras-mediated oncogenesis will be important to establish. One major consequence of these diverse effector signaling events involves changes in gene expression. Some signaling events directly stimulate the activity of specific transcription factors and the number of these factors continues to increase. Other Ras-mediated signaling events, including DNA methylation or histone acetylation, may cause global changes in gene expression. The development and applications of methods, such as microarray analyses and functional proteomics, to evaluate global changes in gene or protein expression will further increase our knowledge of the gene targets of Ras. Hence, this area of Ras research will evolve rapidly in the coming years. The accumulation of information will certainly occur at a pace that greatly exceeds our ability to make sense of these observations. Nevertheless, our utilization of this information will facilitate important advances for understanding the role of Ras in oncogenesis and for the identification of novel therapeutic approaches for cancer diagnosis and treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aktas, H., Cai, H., and Cooper, G.M. (1997). Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIPJ. Mol.Cell.Biol. 17, 3850–3857.
Arber, N., Sutter, T., Miyake, M., Kahn, S.M., Venkatraj, V.S., Sobrino, A., Warburton, D., Holt, P.R., and Weinstein, I.B. (1996). Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 12, 1903–1908.
Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H.R., and Folkman, J. (1997). Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc.Natl.Acad.Sci.U.S.A. 94, 861–866.
Baba, I., Shirasawa, S., Iwamoto, R., Okumura, K., Tsunoda, T., Nishioka, M., Fukuyama, K., Yamamoto, K., Mekada, E., and Sasazuki, T. (2000). Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res. 60, 6886–6889.
Ballin, M., Gomez, D.E., Sinha, C.C., and Thorgeirsson, U.P. (1988). Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem.Biophys.Res.Commun. 154, 832–838.
Bar-Sagi, D. (2001). A Ras by any other name. Mol.Cell Biol. 21, 1441–1443.
Bar-Sagi, D. and Hall, A. (2000). Ras and Rho GTPases: a family reunion. Cell 103, 227–238.
Barbacid, M. (1987). ras genes. Annu.Rev.Biochem. 56, 779–827.
Baruch, R.R., Melinscak, H., Lo, J., Liu, Y., Yeung, O., and Hurta, R.A. (2001). Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol.Int. 25, 411–420.
Bernhard, E.J., Gruber, S.B., and Muschel, R.J. (1994). Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc.Natl.Acad.Sci.U.S.A. 91, 4293–4297.
Bernhard, E.J., Muschel, R.J., and Hughes, E.N. (1990). Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res. 50, 3872–3877.
Bos, J.L. (1989). ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689.
Bourne, H.R., Sanders, D.A., and McCormick, F. (1990). The GTPase superfamily: conserved structure and molecular mechanism. Nature 349, 117–126.
Brtva, T.R., Drugan, J.K., Ghosh, S., Terrell, R.S., Campbell-Burk, S., Bell, R.M., and Der, C.J. (1995). Two distinct Raf domains mediate interaction with Ras. J.Biol.Chem. 270, 9809–9812.
Campbell, S.L., Khosravi-Far, R., Rossman, K.L., Clark, G.J., and Der, C.J. (1998). Increasing complexity of Ras signaling. Oncogene 17, 1395–1413.
Chambers, A.F. and Tuck, A.B. (1993). Ras-responsive genes and tumor metastasis. Crit.Rev.Oncogenesis 4, 95–114.
Chan, T.O., Rittenhouse, S.E., and Tsichlis, P.N. (1999). AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu.Rev.Biochem, 68, 965–1014.
Charvat, S., Le Griel, C., Chignol, M.C., Schmitt, D., and Serres, M. (1999). Ras-transfection up-regulated HaCaT cell migration: inhibition by Marimastat. Clin.Exp.Metastasis 17, 677–685.
Cheng, M., Sexl, V., Sherr, C.J., and Roussel, M.F. (1998). Assembly of cyclin D-dependent kinase and titration of p27Kipl regulated by mitogen-activated protein kinase kinase (MEK1). Proc.Natl.Acad.Sci.U.S.A. 95, 1091–1096.
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O’Hagan, R., Pantginis, J., Zhou, H., Horner, J.W., Cordon-Cardo, C., Yancopoulos, G.D., and DePinho, R.A. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472.
Ciardiello, F., Kim, N., Hynes, N., Jaggi, R., Redmond, S., Liscia, D.S., Sanfilippo, B., Merlo, G., Callahan, R., Kidwell, W.R., and. (1988). Induction of transforming growth factor alpha expression in mouse mammary epithelial cells after transformation with a point-mutated c-Ha-ras protooncogene. Mol.Endocrinol. 2, 1202–1216.
Ciardiello, F., McGeady, M.L., Kim, N., Basolo, F., Hynes, N., Langton, B.C., Yokozaki, H., Saeki, T., Elliott, J.W., and Masui, H. (1990). Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth Differ. 1, 407–420.
Cichowski, K. and Jacks, T. (2001). NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593–604.
Clark, G.J. and Der, C.J. (1993). Oncogenic activation of Ras proteins. In GTPases in Biology I. B.F. Dickey and L. Birnbaumer, eds, (Berlin; Springer Verlag), pp. 259–288.
Clark, G.J. and Der, C.J. (1995). Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res.Treat. 35, 133–144.
Collard, J.G., Schijven, J.F., and Roos, E. (1987). Invasive and metastatic potential induced by ras-transfection into mouse BW5147 T-lymphoma cells. Cancer Res. 47, 754–759.
Coussens, L.M. and Werb, Z. (1996). Matrix metallo proteinases and the development of cancer. Chem.Biol. 3, 895–904.
Cowley, S., Paterson, H., Kemp, P., and Marshall, C.J. (1994). Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH3T3 cells. Cell 77, 841–852.
Cox, A.D. (2001). Farnesyl transferase inhibitors: potential role in the treatment of cancer. Drugs 61, 723–732.
Cox, A.D. and Der, C.J. (1997). Farnesyl transferase inhibitors and cancer treatment: targeting simply Ras? Biochim.Biophys.Acta 1333, F51–F71
Cullen, P.J. (2001). Ras effectors: Buying shares in Ras plc. Curr.Biol. 11, R342–R344
Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J 351, 95–105.
Engel, G., Popowicz, P., Marshall, H., Norling, G., Svensson, C., Auer, G., Akusjarvi, G., and Linder, S. (1992). Elevated stromelysin-1 and reduced collagenase-IV expression in invasive rat embryo fibroblasts expressing E1A deletion mutants + T24-H-ras. Int.J.Cancer 51, 761–766.
Feig, L.A. and Buchsbaum, R.J. (2002). Cell signaling: life or death decisions of ras proteins. Curr.Biol. 12, R259–R261
Feig, L.A., Urano, T., and Cantor, S. (1996). Evidence for a Ras/Ral signaling cascade. Trends Biochem.Sci. 21, 438–441.
Fidler, I.J. (1999). Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother.Pharmacol. 43 Suppl, S3–10.
Filmus, J., Robles, A.I., Shi, W., Wong, M.J., Colombo, L.L., and Conti, C.J. (1994). Induction of cyclin D1 over expression by activated ras, Oncogene 9, 3627–3633.
Filmus, J., Shi, W., and Spencer, T. (1993). Role of transforming growth factor alpha (TGF-α) in the transformation of ras-transfected rat intestinal epithelial cells. Oncogene 8, 1017–1022.
Finco, T.S., Westwick, J.K., Norris, J.L., Beg, A.A., Der, C.J., and Baldwin Jr., A.S. (1997). Oncogenic Ha-Ras-induced signaling activates NF-kB transcriptional activity, which is required for cellular transformation. J.Biol.Chem. 272, 24113–24116.
Fukushima, H., Yamamoto, H., Itoh, F., Nakamura, H., Min, Y., Horiuchi, S., Iku, S., Sasaki, S., and Imai, K. (2001). Association of matrilysin mRNA expression with K-ras mutations and progression in pancreatic ductal adenocarcinomas. Carcinogenesis 22, 1049–1052.
Gangarosa, L.M., Sizemore, N., Graves-Deal, R., Oldham, S.M., Der, C.J., and Coffey, R.J. (1997). A Raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J.Biol.Chem. 272, 18926–18931.
Giambernardi, T.A., Grant, G.M., Taylor, G.P., Hay, R.J., Maher, V.M., McCormick, J.J., and Klebe, R.J. (1998). Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 16, 483–496.
Gille, H. and Downward, J. (1999). Multiple ras effector pathways contribute to G(l) cell cycle progression. J.Biol.Chem. 274, 22033–22040.
Gire, V., Marshall, C.J., and Wynford-Thomas, D. (1999). Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras. Oncogene 18, 4819–4832.
Glick, A.B., Sporn, M.B., and Yuspa, S.H. (1991). Altered regulation of TGF-beta 1 and TGF-alpha in primary keratinocytes and papillomas expressing v-Ha-ras. Mol.Carcinog. 4, 210–219.
Godwin, A.K. and Lieberman, M.W. (1990). Early and late responses to induction of rasT24 expression in Rat-1 cells. Oncogene 5, 1231–1241.
Granger-Schnarr, M., Benusiglio, E., Schnarr, M., and Sassone-Corsi, P. (1992). Transformation and transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial represser. Proc.Natl.Acad.Sci.USA 89, 4236–4239.
Greulich, H. and Erikson, R.L. (1998). An analysis of Mek1 signaling in cell proliferation and transformation. J.Biol.Chem. 273, 13280–13288.
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marmé, D. (1995). Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J.Biol.Chem. 270, 25915–25919.
Gum, R., Lengyel, E., Juarez, J., Chen, J.H., Sato, H., Seiki, M., and Boyd, D. (1996). Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-l sequences. J. Biol. Chem. 271, 10672–10680.
Gum, R., Wang, H., Lengyel, E., Juarez, J., and Boyd, D. (1997). Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase-and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 14, 1481–1493.
Habets, G.G.M., Knepper, M., Sumortin, J., Choi, Y.J., Sasazuki, T., Shirasawa, S., and Bollag, G. (2001). Chip array screening for Ras-regulated genes. Methods Enzymol. 332, 245–260.
Hanahan, D. and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70.
Heinrich, J., Bosse, M., Eickhoff, H., Nietfeld, W., Reinhardt, R., Lehrach, H., and Moelling, K. (2000). Induction of putative tumor-suppressing genes in Rat-1 fibroblasts by oncogenic Raf-1 as evidenced by robot-assisted complex hybridization. J.Mol.Med. 78, 380–388.
Henry, D.O., Moskalenko, S.A., Kaur, K.J., Fu, M., Pestell, R.G., Camonis, J.H., and White, M.A. (2000). Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappa B. Mol.Cell Biol 20, 8084–8092.
Himelstein, B.P., Lee, E.J., Sato, H., Seiki, M., and Muschel, R.J. (1997). Transcriptional activation of the matrix metalloproteinase-9 genein an H-ras and v-myc transformed ratembryo cell line. Oncogene 14, 1995–1998.
Hua, J. and Muschel, R.J. (1996). Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56, 5279–5284.
Jayaraman, G., Srinivas, R., Duggan, C., Ferreira, E., Swaminathan, S., Somasundaram, K., Williams, J., Hauser, C., Kurkinen, M., Dhar, R., Weitzman, S., Buttice, G., and Thimmapaya, B. (1999). p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter. J.Biol.Chem. 274,17342–17352.
Johnson, R., Spiegelman, B., Hanahan, D., and Wisdom, R. (1996). Cellular transformation and malignancy induced by ras require c-jun. Mol.CeIl.Biol. 16, 4504–4511.
Joneson, T., White, M.A., Wigler, M.H., and Bar-Sagi, D. (1996). Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 271, 810–812.
Kerkhoff, E. and Rapp, U.R. (1997). Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol.Cell.Biol. 17, 2576–2586.
Khosravi-Far, R., Solski, P.A., Kinch, M.S., Burridge, K., and Der, C.J. (1995). Activation of Rac and Rho, and mitogen activated protein kinases, arer equiredfor Ras transformation. Mol.Cell.Biol. 15,6443–6453.
Khosravi-Far, R., White, M.A., Westwick, J.K., Solski, P.A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M.H., and Der, C.J. (1996). Oncogenic Rasactivation of Raf/MAP kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol.Cell.Biol. 16, 3923–3933.
Khwaja, A., Rodriguez-Viciana, P., Wennström, S., Warne, P.H., and Downward, J. (1997). Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. MBO J. 16,2783–2793.
Kim, D., Kim, S., Koh, H., Yoon, S.O., Chung, A.S., Cho, K.S., and Chung, J. (2001). Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15, 1953–1962.
Kirstein, M., Sanz, L., Quinones, S., Moscat, J., Diaz-Meco, M.T., and Saus, J. (1996). Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene. J.Biol.Chem. 271,18231–18236.
Konishi, T., Huang, C.L., Adachi, M., Taki, T., Inufusa, H., Kodama, K., Kohno, N., and Miyake, M. (2000). The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int.J.Oncol. 16, 501–511.
Laderoute, K.R., Alarcon, R.M., Brody, M.D., Calaoagan, J.M., Chen, E.Y., Knapp, A.M., Yun, Z., Denko, N.C., and Giaccia, A.J. (2000). Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin.Cancer Res. 6, 2941–2950.
Ladha, M.H., Lee, K.Y., Upton, T.M., Reed, M.F., and Ewen, M.E. (1998). Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol.Cell Biol. 18, 6605–6615.
Langer, S.J., Bortner, D.M., Roussel, M.F., Sherr, C.J., and Ostrowski, M.C. (1992). Mitogenic signaling by colony-stimulating factor 1 and ras issuppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol.Cell.Biol. 12, 5355–5362.
Lavoie, J.N., L’Allemain, G., Brunet, A., Müller, R., and Pouysségur, J. (1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOOGMAPK pathway. J.Biol.Chem. 271, 20608–20616.
Leevers, S.J., Paterson, H.F., and Marshall, C.J. (1994). Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411–414.
Liang, P., Averboukh, L., Zhu, W., and Pardee, A.B. (1994). Ras activation of genes: Mob-1 as a model. Proc.Natl.Acad.Sci.U.S.A 91, 12515–12519.
Liu, J.J., Chao, J.R., Jiang, M.C., Ng, S.Y., Yen, J.J., and Yang-Yen, H.F. (1995). Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol.Cell Biol. 15, 3654–3663.
LoSardo, J.E., Goggin, B.S., Bohoslawec, O., and Neri, A. (1995). Degradation of endothelial cell matrix collagen is correlated with induction of stromelysin by an activated ras oncogene. Clin.Exp.Metastasis 13, 236–248.
Marshall, C. (1999). How do small GTPase signal transduction pathways regulate cell cycle entry? Curr.Opin.Cell.Biol. 11, 732–736.
Marshall, C.J. (1996). Ras effectors. Curr.Op.Cell Biol. 8, 197–204.
Marshall, C.J., Vousden, K., and Ozanne, B. (1985). The involvement of activated ras genes in determining the transformed phenotype. Proc.R.Soc.Lond B Biol.Sci. 226, 99–106.
Matrisian, L.M. (1999). Cancer biology: extracellular proteinases in malignancy. Curr.Biol. 9, R776–R778
Mayo, M.W., Wang, C.Y., Cogswell, P.C., Rogers-Graham, K.S., Lowe, S.W., Der, C.J., and Baldwin, A.S.J. (1997). Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 278, 1812–1815.
Mazure, N.M., Chen, E.Y., Laderoute, K.R., and Giaccia, A.J. (1997). Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90, 3322–3331.
McCarthy, S.A., Samuels, M.L., Pritchard, C.A., Abraham, J.A., and McMahon, M. (1995). Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 9, 1953–1964.
McCawley, L.J. and Matrisian, L.M. (2001). Tumor progression: defining the soil round the tumor seed. Curr.Biol. 11, R25–R27
McFall, A., Ulku, A., Lambert, Q.T., Kusa, A., Rogers-Graham, K., and Der, CJ. (2001). Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol.Cell Biol. 21, 5488–5499.
Meade-Tollin, L.C., Boukamp, P., Fusenig, N.E., Bowen, C.P., Tsang, T.C., and Bowden, G.T. (1998). Differential expression of matrix metalloproteinases in activated c-ras-Ha-transfected immortalized human keratinocytes. Br.J.Cancer 77, 724–730.
Medema, R.H., Kops, G.J., Bos, J.L., and Burgering, B.M. (2000). AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–787.
Milanini, J., Vinals, F., Pouyssegur, J., and Pages, G. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J.Biol.Chem. 273, 18165–18172.
Moon, A., Kim, M.S., Kim, T.G., Kim, S.H., Kim, H.E., Chen, Y.Q., and Kim, H.R. (2000). H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int.J.Cancer 85, 176–181.
Morrison, D.K. and Cutler, R.E., Jr. (1997). The complexity of Raf-1 regulation. Curr.Op.Cell Biol. 9, 174–179.
Normanno, N., Bianco, C., De Luca, A., and Salomon, D.S. (2001). The role of EGF-related peptides in tumor growth. Front Biosci. 6, D685–D707
Ohnami, S., Matsumoto, N., Nakano, M., Aoki, K., Nagasaki, K., Sugimura, T., Terada, M., and Yoshida, T. (1999). Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer.Res. 59, 5565–5571.
Okada, F., Rak, J.W., Croix, B.S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R.S. (1998). Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc.Natl.Acad.Sci.U.S.A. 95, 3609–3614.
Oldham, S.M., Clark, G.J., Gangarosa, L.M., Coffey, R.J., Jr., and Der, C.J. (1996). Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc.Natl.Acad.Sci.USA 93, 6924–6928.
Oliff, A. (1999). Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim.Biophys.Acta 1423, C19–C30
Pruitt, K. and Der, C.J. (2001). Ras and Rho regulation of the cell cycle and transformation. Cancer Lett. 171, 1–10.
Pruitt, K., Pestell, R.G., and Der, C.J. (2000). Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. J.Biol.Chem. 275, 40916–40924.
Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R.S. (1995a). Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575–4580.
Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., Mansour, S.J., Ahn, N.G., and Kerbel, R.S. (2000b). Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490–498.
Reuther, G.W. and Der, C.J. (2000). The Ras branch of small GTPases: Ras family members don’t fall far from the tree. Curr.Opin.Cell Biol. 12, 157–165.
Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M.J., Waterfield, M.D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a directtarget of Ras. Nature 370, 527–532.
Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte, B.M., Pappin, D., Das, P., Waterfield, M.D., Ridley, A., and Downward, J. (1997). Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457–467.
Saez, E., Rutberg, S.E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S.H., and Spiegelman, B.M. (1995). c-fos is required for malignant progression of skin tumors. Cell 82, 721–732.
Schulze, A., Lehmann, K., Jefferies, H.B., McMahon, M., and Downward, J. (2001). Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981–994.
Shao, J., Sheng, H., DuBois, R.N., and Beauchamp, R.D. (2000). Oncogenic Ras-mediated cell growth arrest and apoptosis is associated with increased ubiquitin-dependent cyclin D1 degradation. J.Biol.Chem.
Shapiro, S.D. (1998). Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10, 602–608.
Sherr, C.J, (1996). Cancer cell cycles. Science 274, 1672–1677.
Sherr, C.J. and Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512.
Shields, J.M., Mehta, H., and Der, C.J. (2001a). DNA methylation, and opposing roles of the ERK and p38 mitogen-activated protein kinase cascades, in Ras-mediated downregulation of tropomyosin. Mol. Cell. Biol, submitted
Shields, J.M., Pruitt, K., McFall, A., Shaub, Der, and C.J. (2000). Understanding Ras: “it ain’t over ‘til it’s over”. Trends Cell Biol. 10, 147–153.
Shields, J.M., Rogers-Graham, K., and Der, C.I. (2001b). Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 277, 9790–9799.
Sklar, M.D., Thompson, E., Welsh, M.J., Liebert, M., Harney, J., Grossman, H.B., Smith, M., and Prochownik, E.V, (1991). Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol.Cell.Biol. 11, 3699–3710.
Stokoe, D., Macdonald, S.G., Cadwallader, K., Symons, M., and Hancock, J.F. (1994). Activation of Raf as a result of recruitment to the plasma membrane. Science 264, 1463–1467.
Takuwa, N. and Takuwa, Y. (2001). Regulation of cell cycle molecules by the Ras effector system. Mol. Cell Endocrinol. 177, 25–33.
Thorgeirsson, U.P., Turpeenniemi-Hujanen, T., Williams, J.E., Westin, E.H., Heilman, C.A., Talmadge, J.E., and Liotta, L.A. (1985). NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice, Mol.Cell.Biol. 5, 259–262.
Tokunaga, T., Tsuchida, T., Kijima, H., Okamoto, K., Oshika, Y., Sawa, N., Ohnishi, Y., Yamazaki, H., Miura, S., Ueyama, Y., and Nakamura, M. (2000). Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br.J.Cancer 83, 833–839.
Treiger, B. and Isaacs, J. (1988). Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J.Urol. 140, 1580–1586.
Vanhaesebroeck, B., Leevers, S.J., Panayotou, G., and Waterfield, M.D. (1997). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends.Biochem.Sci. 22, 267–272.
Vousden, K.H., Eccles, S.A., Purvies, H., and Marshall, C.J. (1986), Enhanced spontaneous metastasis of mouse carcinoma cells transfected with an activated c-Ha-ras-1 gene. Int.J.Cancer 37, 425–433.
Ward, Y., Wang, W., Woodhouse, E., Linnoila, I., Liotta, L., and Kelly, K. (2001). Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol.Cell Biol. 21, 5958–5969.
Wasylyk, B., Hagman, J., and Gutierrez-Hartmann, A. (1998). Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem.Sci. 23, 213–216.
Wasylyk, C., Maira, S.M., Sobieszczuk, P., and Wasylyk, B. (1994). Reversion of Ras transformed cells by Ets transdominant mutants. Oncogene 9, 3665–3673.
Webb, C.P., Van Aelst, L., Wigler, M.H., and Woude, G.F. (1998). Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc.Natl.Acad.Sci.U.S.A. 95, 8773–8778.
Westermarck, J. and Kahari, V.M. (1999). Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13, 781–792.
White, F.C., Benehacene, A., Scheele, J.S., and Kamps, M. (1997). VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation—evidence for divergent stabilization pathways. Growth Factors 14, 199–212.
White, M.A., Nicolette, C., Minden, A., Polverino, A., Van Aelst, L., Karin, M., and Wigler, M.H. (1995). Multiple Ras functions can contribute to mammalian cell transformation. Cell 80, 533–541
Wick, M., Lucibello, F.C., and Müller, R. (1992). Inhibition of Fos-and Ras-induced transformation by mutant Fos proteins with structural alterations in functionally different domains. Oncogene 7, 859–867.
Winston, J.T., Coats, S.R., Wang, Y.-Z., and Pledger, W.J. (1996). Regulation of the cell cycle machinery by oncogenic ras. Oncogene 12, 127–134.
Wolfman, A. (2001). Ras isoform-specific signaling: location, location, location. Sci.STKE. 2001, E2
Wolthuis, R.M., de Ruiter, N.D., Cool, R.H., and Bos, J.L. (1997). Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J. 16, 6748–6761.
Woodhouse, E.C., Chuaqui, R.F., and Liotta, L.A. (1997). General mechanisms of metastasis. Cancer 80, 1529–1537.
Yamamoto, H., Itoh, F., Senota, A., Adachi, Y., Yoshimoto, M., Endoh, T., Hinoda, Y., Yachi, A., and Imai, K. (1995). Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. J.Clin.Lab Anal. 9, 297–301.
Yanagihara, K., Nii, M., Tsumuraya, M., Numoto, M., Seito, T., and Seyama, T. (1995). A radiation-induced murine ovarian granulosa cell tumor line: introduction of v-ras gene potentiates a high metastatic ability. Jpn.J.Cancer Res. 86, 347–356.
Yang, J.Q., Zhao, W., Duan, H., Robbins, M.E., Buettner, G.R., Oberley, L.W., and Domann, F.E. (2001). v-Ha-RaS oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-kappaB. Free Radic.Biol.Med. 31, 520–529.
Zhang, R., Averboukh, L., Zhu, W., Zhang, H., Jo, H., Dempsey, P.J., Coffey, R.J., Pardee, A.B., and Liang, P. (1998). Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol.Cell Biol. 18, 6131–6141.
Zuber, J., Tchernitsa, O.I., Hinzmann, B., Schmitz, A.C., Grips, M., Hellriegel, M., Sers, C., Rosenthal, A., and Schafer, R. (2000). A genome-widesurvey of RAS transformation targets. Nat.Genet. 24, 144–152.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Ülkü, A.S., Der, C.J. (2004). Ras Signaling, Deregulation of Gene Expression and Oncogenesis. In: Frank, D.A. (eds) Signal Transduction in Cancer. Cancer Treatment and Research, vol 115. Springer, Boston, MA. https://doi.org/10.1007/0-306-48158-8_8
Download citation
DOI: https://doi.org/10.1007/0-306-48158-8_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7340-3
Online ISBN: 978-0-306-48158-1
eBook Packages: Springer Book Archive